Arbutus Biopharma
ABUS
ABUS
144 hedge funds and large institutions have $389M invested in Arbutus Biopharma in 2024 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 47 increasing their positions, 32 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
11% more funds holding
Funds holding: 130 → 144 (+14)
2.32% more ownership
Funds ownership: 51.23% → 53.55% (+2.3%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Holders
144
Holding in Top 10
4
Calls
$9.3M
Puts
$2.17M
Top Buyers
| 1 | +$7.3M | |
| 2 | +$5.67M | |
| 3 | +$3.2M | |
| 4 |
Morgan Stanley
New York
|
+$2.88M |
| 5 |
BlackRock
New York
|
+$2.57M |
Top Sellers
| 1 | -$4.62M | |
| 2 | -$3.97M | |
| 3 | -$2.52M | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.78M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$995K |